What is Parse Biosciences?
Parse Biosciences is at the forefront of empowering scientific research and accelerating progress in human health and biology through its innovative Evercode platform. This technology enables researchers worldwide to perform transcriptomic and immune profiling without the need for specialized instruments. Headquartered in Seattle, the company's solutions support critical discoveries in areas such as cancer treatment, tissue repair, stem cell therapy, and immunology, fostering breakthroughs in biomedical research.
How much funding has Parse Biosciences raised?
Parse Biosciences has raised a total of $98.5M across 3 funding rounds:
Other Financing Round
$7M
Series B
$41.5M
Series C
$50M
Other Financing Round (2021): $7M with participation from Bioeconomy Capital
Series B (2022): $41.5M led by Marshall Wace, Logos Capital, Bioeconomy Capital, Janus Henderson Group, and Soleus Capital
Series C (2023): $50M supported by Bioeconomy Capital, Janus Henderson Group, Soleus Capital, Saras Capital, Sahsen Ventures, and Marshall Wace
Key Investors in Parse Biosciences
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy. We expect advances in biology to profoundly improve the human condition and contribute to the global economy. Bioeconomy Capital invests primarily in: (i) technologies that enable biological engineering and production; and (ii) companies that use those technologies to produce goods and services.
Janus Henderson Group
Founded in 1934, Janus Henderson Investors is a United Kingdom-based global asset management, investment company formed through the merger of Janus Capital Group and Henderson Group.
Soleus Capital
Soleus Capital is a healthcare investment firm that specializes in innovative life sciences sectors, including biotech, medtech, diagnostics, and genomics. The firm invests across the healthcare lifecycle, targeting both developmental-stage and commercial companies. Their focus is on advancing healthcare solutions through strategic investments in cutting-edge technologies. Soleus Capital aims to support the growth of companies that are shaping the future of healthcare.
What's next for Parse Biosciences?
With its recent Series C financing, Parse Biosciences is poised for significant expansion and further development of its single-cell sequencing technologies. This strategic investment, following substantial Series B backing, indicates strong market confidence in the company's ability to scale its operations and deepen its impact on biomedical research. The company is expected to leverage this capital to enhance its platform capabilities, broaden its market reach, and continue its mission to democratize access to advanced genomic analysis for researchers globally.
See full Parse Biosciences company page
